Pacira Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Pacira Biosciences

29/02/2024 15:27

* Pacira Biosciences Inc  PCRX.OQ  reported quarterly
adjusted
earnings of 89 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of 80 cents.  The mean expectation of
nine analysts for the quarter was for earnings of 88 cents per
share. Wall Street expected results to range from 75 cents to 98
cents per share.
    * Revenue rose 5.4% to $181.24 million from a year ago;
analysts
expected $181.66 million. 
    * Pacira Biosciences Inc's reported EPS for the quarter was
50
cents​.
    * The company reported quarterly net income of $24.87
million.
    * Pacira Biosciences Inc shares had fallen by 11.4% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Pacira
Biosciences Inc is $45.00 
This summary was machine generated from LSEG data February 29 at
03:26 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      0.88           0.89           Beat
 Sep. 30 2023      0.78           0.72           Missed
 Jun. 30 2023      0.76           0.78           Beat
 Mar. 31 2023      0.62           0.53           Missed